Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Completed · Not applicable

Conditions studied: Mild Cognitive Impairment, Metabolic Syndrome

In brief

The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts in global DNA (deoxyribonucleic acid) methylation (away from nutrient availability and toward biosynthesis) are initiated by chronic metabolic inflexibility, over-activation of the mTOR (mammalian target of rapamycin) pathway, and the deregulation of neural oxidative phosphorylation.

Key facts

Study ID

NCT03319173

Run by

Bristlecone Health, Inc.

People needed

98

Starts

2017-10-15

Expected to finish

2018-09-30

Last updated by the study team

2019-11-12

Who can join

Age: 35 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or Female (age 35-80)
• Previously diagnosed with MetS and/or T2DM as measured by possessing at least two of the following physiological measures: type 2 diabetes, BMI > 30, HgA1c > 5.7%, waist/height ratio > .6, fasting glucose > 125 mg/dL
• Subjective Memory Complaints (SCM) - Subjects score > 3 'yes' answers on the Subjective Memory Complaints Questionnaire
• Previously diagnosed with Mild Cognitive Impairment (MCI)

You may not qualify if…

• Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease

Where it is running

• Bristlecone Health, Inc. — Maple Grove, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.